Skip to main content
. 2021 Jul 6;113(5):1452–1460. doi: 10.1016/j.athoracsur.2021.06.026

Figure 4.

Figure 4

Monthly trends over time in the utilization of six adjunctive therapies in patients with COVID-19 while supported with extracorporeal membrane oxygenation (ECMO) during the 9 months of analysis: anti-interleukin-6–receptor monoclonal antibodies (tocilizumab or sarilumab [green line]); antiviral medications (remdesivir [brown line]); convalescent plasma (purple line); hydroxychloroquine (blue line); Flolan (prostaglandin [yellow line]); and intravenous steroids (gray line).